CIK细胞治疗晚期肝癌的临床观察

Clinical Study on the Treatment of Patients with Advanced Liver Cancer by CIK Cells

目的观察CIK细胞治疗晚期肝癌的临床疗效。方法体外培养CIK细胞,14 d后分次回输给患者,观察患者治疗前后瘤体大小、肿瘤标志物、免疫指标、临床症状、生活质量、卡氏评分等的变化,并记录生存期。结果晚期肝癌治疗前后肿瘤标志物CA199和AFP比较差异有统计学意义(P<0.05),CD4、CD19、CD3/CD16+CD56+比较差异均有统计学意义(P<0.05);治疗后患者临床症状比治疗前有明显改善,差异有统计学意义(P<0.05);卡氏评分提高率为73.91%。结论CIK细胞疗法为无手术放疗及化疗适应证的晚期肝癌患者提供了一种延长生存期,改善生活质量的新途径。

Objective To estimate the clinical eftects on patients with advanced liver cancer by cytokine-induced killer cells （CIK）. Meth- ods CIK cells were cultured in vitro,then were transfused back to 46 patients with advanced liver cancer after two weeks. The changes of tumor weight, immunity indexes, tumor markers, life quality, and the Karnofsky＇ s grade were observed, and the survival time was recorded. Results The CA199 and AFP from patients with advanced liver cancer after treatment are significantly lower than that before treatment （P 〈 0.05）, the CD4, CD19, CD3/CD16^＋ CD56^＋ from patients with liver cancer after treatment were significantly higher than that before treatment （P 〈 0.05 ）. The clinical symptoms of patients after treatment have a significant improvement as compared with before treatment. Karnofsky＇ s grade increased rate was 73.91%. Conclusion CIK cells therapy can improve survival quantity and prolong survival period, which probably provide a new strategy for patients with advanced liver cancer.